Cover Image
市場調查報告書

腎細胞癌:KOL(關鍵意見領導者)考察(2017年)

RCC: KOL Insight [2017]

出版商 FirstWord 商品編碼 531833
出版日期 內容資訊 英文
商品交期: 最快1-2個工作天內
價格
Back to Top
腎細胞癌:KOL(關鍵意見領導者)考察(2017年) RCC: KOL Insight [2017]
出版日期: 2017年07月01日 內容資訊: 英文
簡介

本報告介紹了腎細胞癌(RCC)的主要上市藥劑及處於開發階段的藥劑,並彙整北美及歐洲12位關鍵意見領導者(KOL)的各種見解。

調查藥物

  • 已上市藥劑
    • 紓癌特 (sunitinib; Pfizer)
    • 福退癌(pazopanib; Novartis)
    • 蕾莎瓦 (sorafenib; Amgen/Bayer)
    • 抑癌特 (axitinib; Pfizer)
    • Cabometyx (cabozantinib; Exelixis)
    • Lenvima/Kisplyx (lenvatinib; Eisai)
    • 癌思停 (bevacizumab; Roche)
    • 癌伏妥 (everolimus; Novartis)
    • 特癌適 (temsirolimus; Pfizer)
    • Opdivo (nivolumab; Bristol-Myers Squibb)
  • 候補藥物
    • Tivozanib (Tivopath; AVEO Oncology)
    • Pembrolizumab (Keytruda; Merck & Co.)
    • Atezolizumab (Tecentriq; Roche)
    • Avelumab (Bavencio; Merck Group/Pfizer)
    • Rocapuldencel-T (AGS 003:Argos Therapeutics)

主要論點

  • RCC治療中免疫療法的使用
    • 未來的發展以及對治療策略的影響?
  • 作為第一選項雙重免疫療法、免疫療法/VEGF-TKI併用療法
    • 第三期試驗的宿主正在進行評估
    • 併用療法作為第一選項的可能性,KOL如何看待?
  • 對於單一藥物第一選擇的Sutent (Pfizer)及Votrient(Novartis)的見解
    • 激烈競爭中的展望?
  • KOL對於IMmotion 150第二期試驗的結果有何看法?
    • Tecentriq與Avastin、Sutent的併用療法比較
    • 併用療法整體的可能性
  • KOL對CABOSUN第二期試驗數據的想法
    • KOL對於Cabometyx作為第一選擇藥物潛力的想法
  • Bristol-Myers Squibb的Opdivo
    • 成長為第二選擇藥物
    • KOL所見優缺點及對使用的影響
  • 有效輔助療法雖然不夠充足,複數製劑正在臨床接受評估
    • KOL對於VEGF TKI作為免疫佐劑以及免疫療法的可能性有何看法?
目錄

How will new combination regimens impact the RCC treatment landscape?

The treatment of advanced RCC has been transformed in recent years as VEGF, TKI and mTOR inhibitors have taken centre stage. KOLs now argue that the first-line treatment of advanced RCC is on the cusp of a second wave of change. At the forefront is a multitude of immunotherapy-based combination regimens that look set to transform first-line therapy, including Keytruda/Inlyta, Bavencio/Inlyta, Tecentriq/Avastin, Cabometyx/Opdivo±Yervoy and Keytruda/Lenvima. The adjuvant setting is also set to become a key battleground with multiple agents in Phase III trials. What will be the critical factors for success as the rapidly evolving treatment armamentarium leads to ever more complex decision making for oncologists? In this report six US and six EU KOLs offer their candid insights on ten marketed therapies and five pipeline drugs.

Take a tour of the report now:

  • Methodology
  • Research Objectives
  • Questions Asked
  • See the RCC therapies covered
  • Find out who the 6 US and 6 European KOLs are
  • Sample Pages

Top Takeaways:

  • How is the future use of immunotherapies for the treatment of RCC likely to evolve and how will their use impact current treatment strategies?
  • A host of Phase III trials are evaluating dual immunotherapy and immunotherapy/VEGF-TKI combination regimens in the first-line setting. How do KOLs view the potential for these combinations to be used in first-line treatment?
  • How are Pfizer's Sutent and Novartis' Votrient viewed as first-line monotherapies and what will the future hold for them as competition escalates?
  • How do KOLs view the results of the Phase II IMmotion 150 trial comparing Tecentriq in combination with Avastin versus Sutent, and the overall potential for this combination?
  • How convinced are KOLs by the Phase II CABOSUN data, and do they view the potential for Cabometyx in the frontline setting?
  • Bristol-Myers Squibb's Opdivo has gained momentum in the second-line setting. What do KOLs perceive as the advantages and disadvantages of Opdivo, and how do these influence its usage?
  • There is currently a lack of effective adjuvant therapies, but a number of agents are under clinical evaluation in this setting. How do KOLs view the potential for VEGF TKIs and immunotherapies to be used as adjuvant therapy?

Quotes:

“We will treat in a more diverse way, and in five years' time we should be able to tell which patients should receive a more intense immunotherapy combination versus those that might receive a TKI/ immunotherapy combination, versus those [candidates] for single-agent, less intense, treatment.” EU Key Opinion Leader.

“What we need to address is the question of a cure for patients; it is good to improve survival, it is good to improve PFS, but what we want to improve is the cure rate. That is what we should try to achieve with these combinations, with two or even three agents.” US Key Opinion Leader.

Sample of therapies covered:

Marketed Therapies

  • Sutent (sunitinib; Pfizer)
  • Votrient (pazopanib; Novartis)
  • Nexavar (sorafenib; Amgen/Bayer)
  • Inlyta (axitinib; Pfizer)
  • Cabometyx (cabozantinib; Exelixis)
  • Lenvima/Kisplyx (lenvatinib; Eisai)
  • Avastin (bevacizumab; Roche)
  • Afinitor (everolimus; Novartis)
  • Torisel (temsirolimus; Pfizer)
  • Opdivo (nivolumab; Bristol-Myers Squibb)

Pipeline Therapies

  • Tivozanib (Tivopath; AVEO Oncology)
  • Pembrolizumab (Keytruda; Merck & Co.)
  • Atezolizumab (Tecentriq; Roche)
  • Avelumab (Bavencio; Merck Group/Pfizer)
  • Rocapuldencel-T (AGS 003; Argos Therapeutics)

KOLs from North America

  • Neeraj Agarwal, Associate Professor in the Division of Oncology, Department of Medicine, University of Utah School of Medicine, Salt Lake City, UT
  • Ronald M Bukowski, Professor of Medical Oncology, Bukowski Consulting, OH (previously, Cleveland Clinic, Cleveland, OH)
  • Robert A Figlin, Professor of Hematology/Oncology, Samuel Oschin Comprehensive Cancer Institute, Cedars-Sinai Medical Center, Los Angeles, CA
  • Eric Jonasch, Professor, Department of Genitourinary Medical Oncology, University of Texas MD Anderson Cancer Center, Houston, TX
  • Robert Motzer, Professor of Medical Oncology, Memorial Sloan Kettering Cancer Center, New York, NY
  • Brian Rini, Professor of Medicine, Lerner College of Medicine, The Cleveland Clinic Taussig Cancer Center, Cleveland, OH

KOLs from Europe

  • Bernard Escudier, Professor of Medical Oncology, Institut Gustave Roussy, Villejuif, France
  • Stephane Oudard, Professor of Medical Oncology, Georges Pompidou Hospital, Paris, France
  • Giuseppe Procopio, Professor of Medicine, Fondazione IRCCS - Istituto Nazionale dei Tumori, Milan
  • Anonymous KOL, Professor of Haematology and Oncology, major university medical centre, Germany
  • Anonymous KOL, Professor of Haematology and Oncology, major university hospital, Germany
  • Anonymous KOL, Professor and Chairman of the Department of Urology, major university hospital, Germany
Back to Top